NCT04933942View on ClinicalTrials.gov

Phase II Trial of Romiplostim for Thrombocytopenia Induced by Lomustine at First Progression of MGMT Promoter-meth Glioblastoma

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

September 13, 2022

Primary Completion Date

December 19, 2022

Study Completion Date

December 19, 2022

Conditions
First Progression of MGMT Promoter-methylated Glioblastoma
Interventions
DRUG

Lomustine

Oral administration of Lomustine

DRUG

Romiplostim

Subcutaneous administration of Romiplostim

Trial Locations (5)

28034

Hospital Universitario Ramon y Cajal, Madrid

28041

Hospital Universitario 12 De Octubre, Madrid

08036

Hospital Clinic Universitari de Barcelona, Barcelona

Unknown

Oncology Institute of Southern Switzerland, Bellinzona

UniversitaetsSpital, Zurich

Sponsors

Collaborators (1)

Amgen
All Listed Sponsors
collaborator

Amgen

INDUSTRY

lead

European Organisation for Research and Treatment of Cancer - EORTC

NETWORK